# The Women TDF-FTC Benchmark Study

> **NCT05057858** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Washington** · enrollment: 72 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** co-formulated 300 mg TDF/ 200mg FTC

## Key facts

- **NCT ID:** NCT05057858
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-04-25
- **Primary completion:** 2025-01-31
- **Final completion:** 2025-01-31
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2024-08-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05057858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05057858, "The Women TDF-FTC Benchmark Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05057858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*